Patent intelligence · US
US 11672762
Onapristone extended-release compositions and methods
Onapristone extended-release compositions and methods
Patent details — US 11672762
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 13, 2023
- Expiration
- Jun 8, 2043
- Applicant
- CONTEXT BIOPHARMA, INC.
- Claims
- 21
- CPC classes
- A61K, A61K31/575, A61K9/20, A61K9/2054
Quick answer
US 11672762 (Onapristone extended-release compositions and methods) is held by CONTEXT BIOPHARMA, INC.. Status: granted. Granted Jun 13, 2023. Expires Jun 8, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CONTEXT BIOPHARMA, INC.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/575, A61K9/20, A61K9/2054, A61P, A61P35/00
More from CONTEXT BIOPHARMA, INC.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11672762?
US 11672762 (Onapristone extended-release compositions and methods) is held by CONTEXT BIOPHARMA, INC.. Status: granted. Granted Jun 13, 2023. Expires Jun 8, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11672762?
CONTEXT BIOPHARMA, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 11672762 expire?
Our index shows an expiration date of Jun 8, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.